Amnovis and BAAT Medical have set up a partnership to jointly offer an innovative and fast-turnaround process for 3D printed medical devices. Both complementary companies jointly span the complete process, from initial design idea over medical engineering to legal manufactured devices ready for use.
The business focus and technology expertise shared by Amnovis and BAAT Medical, lead to more innovative business models and better 3D printed medical devices. Their joint technology roadmap, focused on the development of new medical device applications and the validation of state-of-the-art AM technologies and related processes, pushes medical device innovation. This enables medical device startups and OEMs to benefit from faster time to market of 3D printed medical devices that excel in patient outcome.
Over the past decades, Additive Manufacturing (AM) has built a reputation of innovation in the medical devices industry. BAAT Medical has pioneered the engineering and development of 3D printed spinal fusion implants, resulting in multiple CE marks and FDA approvals and more than 50,000 implants manufactured to date. The Amnovis’ founders have a proven track record, going back to 2008, in using AM to make high-end products. They were among the first to employ L-PFB for printing titanium medical devices, such as orthopedic and spinal implants.
The collaboration between Amnovis and BAAT Medical combines the best of both companies. Together, they have a more comprehensive view on how to optimally tune design and development as well as material selection and manufacturing in context of specific AM medical device applications. Both companies work on a joint technology and application roadmap and actively validate new AM technologies to set new standards for specific medical device types. They align these efforts with the business potential and time to market of new AM technologies in the medical sector. As part of this effort, they drill down deeper on AM materials and post-processing methods as well as process automation and validation.
Ruben Wauthle, CEO and Co-founder of Amnovis: “We are extremely proud to collaborate with BAAT Medical. We see great potential in jointly innovating various AM medical device applications. We know each other for years, share the same innovative drive, and collaborate intensively to better align design and development with material selection and manufacturing”
He added, “As preferred partners, our joint offering comprises of the complete process for customers and prospects to aim high and move fast, while removing hurdles in medical device development, validation and manufacturing. At Amnovis, we rely on our comprehensive AM workflow and production platform, which is entirely ISO 13485:2016 certified. Digital process automation enables us to provide full traceability and repeatability to flexibly scale up manufacturing of standard and patient-specific AM medical devices.”
Gert Nijenbanning, Managing Director of BAAT Medical: “It is great to intensify our collaboration with the AM innovators of Amnovis, with whom we successfully worked with before. We believe that efficiency in development and production throughout the whole chain is essential to keep investments in innovations of medical devices feasible, especially for European markets where the MDR is a reality. Together we want to build on the complementary expertise of Amnovis and BAAT Medical to collaborate and take 3D printing of medical devices to the next level.”
Nijenbanning noted, “As preferred partners, we are able to cover the complete process, from initial idea to a certified product. We partner to optimally use the possibilities of current and future AM technologies as part of new business models for medical devices with improved patient outcomes. Amnovis and BAAT Medical, together, push the innovative edge of medical device OEMs and move faster through the development, validation and manufacturing stages.”
